Another HSV-2 vaccine expert joins Redbiotec
Redbiotec announces today the appointment of Research Associate Professor Sita Awasthi from [...]
Three new patents for Redbiotec’s Herpes simplex vaccine program
Redbiotec has filed a new patent application covering its novel [...]
Redbiotec at J.P. Morgan 34th Healthcare Conference in SF
Redbiotec will attend JPM 34th Healthcare Conference in San Francisco starting January [...]
Leading HSV expert joins Redbiotec
Redbiotec announces today the appointment of Professor & Director Lbachir [...]
Perfect start into 2015 – acquisition of CMV program by Pfizer
The announcement on January 5th of the acquisition of Redvax, spin-off of [...]
Pfizer Acquires Redvax GmbH – a spin-off from Redbiotec AG
Excellent news! Press release (Source: Business Wire). Nasdaq WSJ
Continuous Media Attention to Redbiotec
Interviews in Biopharma-Reporter and Labmanager portray Redbiotec and its innovative approach to novel vaccines. [...]
Collaboration with Duke University to study immune responses against complex CMV antigens
Redbiotec and the research group of Dr. Sallie Permar, MD [...]
Redbiotec and GE Healthcare Collaborate to Advance CMV Vaccine Development and Manufacturing
"GE Healthcare Life Sciences seeks to collaborate with world-wide biotechnology [...]
Duke Researcher Sallie Permar, MD PhD, joins Redbiotec’s Scientific Advisory Board
Redbiotec announces today the appointment of Dr. Sallie Permar, MD [...]